AU2022374786A1 - Tadalafil oral suspension - Google Patents

Tadalafil oral suspension Download PDF

Info

Publication number
AU2022374786A1
AU2022374786A1 AU2022374786A AU2022374786A AU2022374786A1 AU 2022374786 A1 AU2022374786 A1 AU 2022374786A1 AU 2022374786 A AU2022374786 A AU 2022374786A AU 2022374786 A AU2022374786 A AU 2022374786A AU 2022374786 A1 AU2022374786 A1 AU 2022374786A1
Authority
AU
Australia
Prior art keywords
preferably comprised
comprised
still
tadalafil
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022374786A
Other languages
English (en)
Inventor
Ester Duart González
Antonia GÓMEZ CALVO
Raquel HORCAJADA CÓRDOBA
José Carlos IGLESIAS SÁNCHEZ
Ángel Muñoz Ruiz
Antonio PORTOLÉS PÉREZ
Guillermo RUBIO MENCO
Luis Narciso SANTÉ SERNA
Nuria SANZ MENÉNDEZ
Emilio VARGAS CASTRILLÓN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider SA filed Critical Farmalider SA
Publication of AU2022374786A1 publication Critical patent/AU2022374786A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022374786A 2021-10-25 2022-10-24 Tadalafil oral suspension Pending AU2022374786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382964 2021-10-25
EP21382964.1 2021-10-25
PCT/EP2022/079659 WO2023072872A1 (en) 2021-10-25 2022-10-24 Tadalafil oral suspension

Publications (1)

Publication Number Publication Date
AU2022374786A1 true AU2022374786A1 (en) 2024-06-13

Family

ID=78528864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022374786A Pending AU2022374786A1 (en) 2021-10-25 2022-10-24 Tadalafil oral suspension

Country Status (10)

Country Link
US (1) US20250241911A1 (https=)
EP (1) EP4422599B1 (https=)
JP (1) JP2024541013A (https=)
CN (1) CN118284408A (https=)
AU (1) AU2022374786A1 (https=)
CA (1) CA3235733A1 (https=)
DK (1) DK4422599T3 (https=)
FI (1) FI4422599T3 (https=)
MX (1) MX2024005048A (https=)
WO (1) WO2023072872A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US20060147531A1 (en) 2003-07-01 2006-07-06 Mojca Segula Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate
SI21637A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR20070021806A (ko) 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
KR20160021095A (ko) 2013-06-21 2016-02-24 욱크하르트 리미티드 탐술로신 또는 이의 염의 약학 조성물
CZ2015225A3 (cs) 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
EP3498264B1 (en) * 2016-08-12 2023-11-08 Hanmi Pharm. Co., Ltd. Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets
EP3576741A1 (en) 2017-02-02 2019-12-11 Dukebox SP. Z O.O. A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage

Also Published As

Publication number Publication date
US20250241911A1 (en) 2025-07-31
MX2024005048A (es) 2024-05-10
EP4422599A1 (en) 2024-09-04
DK4422599T3 (da) 2026-03-30
FI4422599T3 (fi) 2026-03-25
CN118284408A (zh) 2024-07-02
EP4422599B1 (en) 2026-01-28
JP2024541013A (ja) 2024-11-06
WO2023072872A1 (en) 2023-05-04
CA3235733A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
EP1239831B1 (en) Improved pharmaceutical compositions for poorly soluble drugs
BRPI0212922B1 (pt) Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição
AU2007338359B2 (en) Pharmaceutical formulation comprising neurokinin antagonist
JP2021185139A (ja) ミラベグロンまたはその塩を含む放出調節用薬剤学的組成物
CA2393737A1 (en) Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption
PT1711169E (pt) Minicomprimidos revestidos de libertação prolongada de cloridrato de venlafaxina.
US20090088424A1 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
EP4422599B1 (en) Tadalafil oral suspension
US20040052847A1 (en) Oral dosage forms of water insoluble drugs and methods of making the same
EP3968955B1 (en) Pharmaceutical oral liquid solution of ivacaftor
EP3644968B1 (en) Levocloperastine fendizoate suspension having enhanced dissolution and resuspendability
AU2020410965B2 (en) Liquid composition comprising ibuprofen and phenylephrine
WO2001089473A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
HK40077494A (en) Liquid composition comprising ibuprofen and phenylephrine
HK40077494B (en) Liquid composition comprising ibuprofen and phenylephrine
Namdev Formulation and Evaluation of Mouth Dissolving Tablets of Metoprolol Tartrate
Patel Formulation, Development and Evaluation of Expectorant Extended Release Tablet
CN119546305A (zh) 泛raf激酶抑制剂的口服液体悬浮液
HK40096982A (zh) 包含美洛昔康的医药组成物
EP2558079A1 (en) Ciprofloxacin dry syrup composition
Rakkanka 1. A novel self-sealing chewable sustained release tablet of acetaminophen, 2. Development and evaluation of novel itraconazole oral formulations, 3. A novel zero order release matrix tablet
HK1198466A1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
HK1198466B (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
HK1172252A (en) Pharmaceutical suspension composition